Trial Profile
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Abacavir; Atazanavir; Cobicistat; Darunavir; Delavirdine; Didanosine; Dolutegravir; Doravirine; Efavirenz; Elvitegravir; Emtricitabine; Lamivudine; Lopinavir; Maraviroc; Nelfinavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Saquinavir; Stavudine; Tenofovir alafenamide; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms BRAAVE 2020
- Sponsors Gilead Sciences
- 06 Mar 2024 Results assessing longitudinal analysis of preexisting Resistance-Associated mutations prior to bictegravir/emtricitabine/tenofovir alafenamide switch, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 10 Dec 2021 Results of pooled analysis (n=1906) assessing virologic outcomes through 48 weeks of B/F/TAF treatment in individuals with pre-existing primary INSTI-R from 7 bictegravir/emtricitabine/tenofovir alafenamide studies (GS-US-380-1489/NCT02607930 and GS-US-380-1490/NCT02607956), (GS-US-380-1844/NCT02603120; GS-US-380-1878/NCT02603107; GS-US-380-4580/NCT03631732; GS-US-380-4030/NCT03110380 and GS-US-380-4449/NCT03405935), published in the JAIDS.
- 30 Oct 2021 Results (n=2079) of pooled analysis assessing the safety and efficacy of switching adults with suppressed HIV to bictegravir/emtricitabine/tenofo - vir alafenamide (B/F/TAF) from 5 studies (Studies 1844, 1878, 4030, 4449, and 4580) presented at the 18th European AIDS Conference